APA (7th ed.) Citation

Amaro, A., Reggiani, F., Fenoglio, D., Gangemi, R., Tosi, A., Parodi, A., . . . Levesque, M. (2023). Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. Journal of Experimental & Clinical Cancer Research (17569966), 42(1), 1. https://doi.org/10.1186/s13046-023-02628-x

Chicago Style (17th ed.) Citation

Amaro, Adriana, et al. "Guadecitabine Increases Response to Combined Anti-CTLA-4 and Anti-PD-1 Treatment in Mouse Melanoma in Vivo by Controlling T-cells, Myeloid Derived Suppressor and NK Cells." Journal of Experimental & Clinical Cancer Research (17569966) 42, no. 1 (2023): 1. https://doi.org/10.1186/s13046-023-02628-x.

MLA (9th ed.) Citation

Amaro, Adriana, et al. "Guadecitabine Increases Response to Combined Anti-CTLA-4 and Anti-PD-1 Treatment in Mouse Melanoma in Vivo by Controlling T-cells, Myeloid Derived Suppressor and NK Cells." Journal of Experimental & Clinical Cancer Research (17569966), vol. 42, no. 1, 2023, p. 1, https://doi.org/10.1186/s13046-023-02628-x.